Clinical trials
Phase 4 Acne Vulgaris trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
71 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 10 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 60 |
| Terminated | 3 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Galderma R&D | 15 |
| Sun Pharmaceutical Industries Limited | 7 |
| Allergan | 6 |
| Bausch Health Americas, Inc. | 6 |
| Stiefel, a GSK Company | 6 |
| Derm Research, PLLC | 5 |
| Wake Forest University | 4 |
| Zeichner, Joshua, M.D. | 2 |
| Almirall, S.A. | 1 |
| Beth Israel Deaconess Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Acne Vulgaris | 71 |
| Hyperpigmentation | 4 |
| Alopecia Areata | 1 |
| Amenorrhea | 1 |
| Cicatrix | 1 |
| Cicatrix, Hypertrophic | 1 |
| Dermoid Cyst | 1 |
| Dyslipidemias | 1 |
| Erythema | 1 |
| Glucosephosphate Dehydrogenase Deficiency | 1 |
Trials
Showing 1 to 25 of 71. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.